PLAUR and cancer: Given the availability of well-characterized anti-uPAR monoclonal antibodies, and the expanding clinical success of ADCs for cancer treatment, the development of ADCs targeting uPAR is expected to open new therapeutic avenues for aggressive cancers, such as TBNC, where there is a paucity of molecular targets.